FARM IP, ENTER WIPO
Developing countries will now have to battle IP issues related to new agricultural technologies at WIPO instead of WTO
Brickbats for compulsory licences
US criticises India and BRIC group for strengthening provisions on life-saving medicines
Spy versus spy and high tech gizmos
From secure manhole covers to Internet tracking systems, NSA has an arsenal of patents
How to save $25 billion and more on drug costs
Patent settlements bring cheaper generics to market early and cut healthcare spending
Strong medicine for weak drug patents
Revocation of Pfizer, Roche patents for lacking inventive step signals healthy trend
Best way to check arsenic residues in rice
Biodiversity—India’s other scandal
CAG slams the national biodiversity authority for allowing questionable patents
Japanese biopiracy of our Ballia barley
Japan’s Sapporo brewery patents Indian barley gene without giving benefit to farmers
Getting the drug equation right
Sonal Matharu reports how fights over counterfeit drugs and low-quality drugs is suppressing the larger issue of drug safety
Public Funded R&D Bill may benefit the private sector
Free trade will bind India
Rotten tomato for Monsanto
US biotech giant's claim on a natural tomato is its latest patent to be revoked by Europe after soy and wheat
The fine line for judges
Judges have recused themselves in a number of cases but there are no clear guidelines on what constitutes conflict of interest
Legislation for a few
Benefits of the Act that encourages conservation of plants reach few farmers
Foss time in India
Microsoft is the most familiar term in the proprietary software industry. The company's penetration in people's minds is so deep that it is often …
MONEYMAKERS
Maths of Gilead's hepatitis C drug
Why US firm's super expensive drug sofosbuvir costs so much and how it can be made at a tenth of current price
Cipla's bitter pill for MNCs
Several eyebrows have been raised over the Cipla offer to supply anti- aids drugs at one-third the current price to developing countries like …
Obama takes first dip
The US becomes the first to join a global patents pool to make AIDS drugs cheaper but health workers are sceptical of the initiative
Access, yes. Sharing, no
The access and benefit-sharing protocol on biodiversity may do little to deter multinationals from grabbing the planet’s resources
ABCDE of Obama’s sales pitch
Evergreen Novartis
The Swiss pharma giant’s challenge to India’s patent law, now in the Supreme Court, may help define drug efficacy
The Kani learning
How benefit-sharing between a research institute and the Kani tribe went awry
Novartis exposes India's weak patent laws. Will generics be kicked out?
Rajasthan opens farm gates
State ties up with Monsanto, other biotech giants to restructure agriculture